logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9999663 B1

PDFFull Text
Date of Patent:
Jun. 19, 2018

Filed:

Sep. 30, 2014

Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use

Applicant:

Pontificia Universidad Catolica DE Chile, Santiago, CL;

Inventors:

Susan Marcela Bueno Ramirez, Santiago, CL;

Alexis Mikes Kalergis Parra, Santiago, CL;

Christian Palavecino Beaumont, Santiago, CL;

Assignee:

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, Santiago, CL;

Attorney:

Lucas & Mercanti, LLP

Primary Examiner:

Brian Gangle

Int. Cl.
CPC ...
A61K 39/155 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/155 (2013.01); A61K 39/12 (2013.01); C12N 7/00 (2013.01); A61K 2039/522 (2013.01); A61K 2039/523 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55594 (2013.01); C12N 2760/18334 (2013.01); C12N 2760/18371 (2013.01); C12N 2760/18534 (2013.01);
Abstract

The present invention relates to an immunogenic formulation to be used in mammals against human Metapneumovirus (hMPV), consisting of a lyophilisate of 1×10ufc/ml of recombinant BCG that expresses the viral protein P of hMPV (of genogroups A1, A2, B1 and B2). The vaccine is derived from the full or partial product of the P gene of hMPV, capable of being used, stabilised and administered in solution without requiring adjuvants. The preparation can also contain combinations of the aforementioned formulations. The formulation is stabilised by means of lyophilisation (conservation range of between 4° C. and 8° C.) in order to be subsequently reconstituted in an adjuvant-free saline solution prior to use.

Find Patent Forward Citations

Bueno Ramirez, Susan. (2018). Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use (U.S. Patent No. 9999663). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9999663

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…